Variation is the disrupts of Proliferation.
Proliferation is the leads to of Proliferation Of An Unripe Clone Of Electric Cell.
Proliferation Of An Unripe Clone Of Electric Cell represents Aml.
Aml is the results in of Multifariousness And Heterogeneousness Of Aml Stem.
Multifariousness And Heterogeneousness Of Aml Stem is the can occur at of Leukemic Shift.
Specialisation is the determines of Specialisation.
Specialisation is the determines of Aml.
Cytogenetical Irregularity associates Aml.
Chromosomal Abnormalcy associates Aml.
Chromosomal Translocations is the encode of Merger Proteins.
Merger Proteins is the causes of Differentiation Arrest.
Acute Promyelocytic Leukaemia is the produces of Pml-Rarα Fusion Protein.
Pml-Rarα Fusion Protein is the binds to of Retinoic Acid Receptor.
Pml-Rarα Fusion Protein is the suppresses of Myeloid-Specific Factor.
Neutropenia is the results from of Aml.
Anaemia is the results from of Aml.
Thrombopenia is the results from of Aml.
Aml is the can cause of Chloroma.
Pathophysiological Mechanics Of Leukemogenesis In Aml is the involves of Epigenetic Induction Of Dedifferentiation.
Transmitted Variation is the contributes to of Epigenetic Induction Of Dedifferentiation.
Epigenetic Enzymes is the produces of Oncometabolite D-Ii-Hydroxyglutarate.
Aml Treatment is the comprises of Chemotherapy.
Aml Treatment is the involves of Haematopoietic Stem Cell Transplantation.
Aml Treatment is the utilizes of Tyrosine Kinase Inhibitors.
Generalisation follows Postremission Therapy.
Generalisation is the treats of Aml.
Postremission Therapy is the prevents of Relapse.
Relapse requires Hematopoietic Stem Cell Transplant.
Gemtuzumab Ozogamicin is the treatment for of Relapse.
Relapse is the enrollment in of Clinical Trial.
Prognostic Factor is the affects of Aml.
Cytogenetics is the influences of Prognostic Factor.
Myelodysplastic Syndrome is the leads to of Secondary Aml.
Molecular Modifications is the impacts of Prognostic Factor.
Flt3-Itd associates Prognostic Factor.
Npm1 associates Prognostic Factor.
Cebpa associates Prognostic Factor.
C-Kit associates Prognostic Factor.
Imatinib And Sunitinib is the inhibits of C-Kit.
Therapeutic Rate In Clinical Trials is the varies in of Aml.
Alfred Armand Louis Marie Velpeau lives Uk.
J.H. Floyd Bennett lives Uk.
Rudolf Virchow lives Uk.
Rudolf Karl Virchow lives Uk.
Paul Ehrlich lives Uk.
Wilhelm Ebstein lives Uk.
Franz Ernst Christian Neumann lives Uk.
Mosler lives Uk.
Otto Naegeli lives Uk.